原发性中晚期肝癌中医综合治疗疗效观察

目的观察比较原发性中晚期肝癌患者行鸦胆子油介入治疗联合内服肝积方和化疗药物灌注栓塞两种治疗方式的疗效。方法将77例原发性肝癌患者随机分为中药治疗组（40例）与西药对照组（37例）。均采用肝动脉介入治疗,观察两组患者的近远期疗效,毒副反应,治疗前后CD3^＋/HLA-DR^＋、CD62P及患者生活质量变化。结果中药治疗组较西药对照组毒副反应发生率明显降低（P〈0.05）,中药治疗组中反应患者细胞免疫功能指标（CD3^＋/HLA-DR^＋）治疗后较治疗前升高,表明患者血液高凝状态指标（CD62P）治疗后较治疗前降低,中药治疗组患者0.5,1年生存率分别为67.6%和38.2%,西药对照组分别为42.4%和16.1%,差异有显著性（P〈0.05）。结论中药治疗可减轻副反应,提高患者生活质量,适当改善远期生存。鸦胆子油乳介入联合内服肝积方治疗是中晚期原发性肝癌有效的治疗方法。

Study of combined treatment with traditional Chinese medicine for advanced primary hepatocarcinoma

Objective To compare the efficacy of transcatheter arterial embolization（TAE） with oleum fructus bruceae combined with oral administration of Ganjifang and transcatheter arterial chemoembolization（TACE） in treatment of advanced primary hepatocarcinoma. Methods Seventy-seven patients with the advanced primary hepatocarcinoma were randomized into 2 groups： observation group treated with traditional Chinese medicine and control group treated with TACE. The near-term and long-term curative effect, the side reaction and toxicity were observed, the change of CD3 ^＋/HLA-DR^＋ （ reflecting the cytoimmunity）, CD62P（ reflecting the high viscosity of blood） and the quality of life （QOL）before and after the treatment were compared. Results The rates of the side reaction and toxicity in the observation group were lower than those in the control group（ P 〈 0.05）. In the observation group, CD3^＋/HLA-DR^＋ rose after the treatment, whereas CD62P decreased. The 0. 5- and 1-year survival rates were 67. 6% and 38. 2% respectively in the observation group and 42. 4% and 16. 1%, respectively in the control group（P 〈 0. 05 ）. Conclusion Combined treatment with traditional Chinese medicine can alleviate the side reaction and toxicity, improve the QOL and raise the long-term survival rate. It is an effective method for treating the patients with advanced primary hepatocarcinoma.